Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, University of Heidelberg.
EMBO Mol Med. 2009 Apr;1(1):6-9. doi: 10.1002/emmm.200900007.
Psychiatric disorders are a common, severe and disabling group of diseases where progress in finding novel molecular targets has been slow. This is partly due to our lack of understanding of the molecular pathophysiology of these conditions as they play out in the brain (Insel & Scolnick, 2006). Since many of these diseases (such as schizophrenia, bipolar disorder or autism) are highly heritable, a genetic approach to dissecting the risk architecture is a promising avenue for molecular medicine; however, variants in single genes frequently present in the population have only small to moderate effects on complex behavioural phenotypes (O'Donovan et al, 2008).
精神障碍是一组常见的、严重的、致残性疾病,在寻找新的分子靶点方面进展缓慢。这在一定程度上是由于我们对这些疾病在大脑中的分子病理生理学的理解不足(Insel & Scolnick,2006)。由于许多这些疾病(如精神分裂症、双相情感障碍或自闭症)具有高度遗传性,因此采用遗传方法来剖析风险结构是分子医学的一个有前途的途径;然而,人群中常见的单基因变异对复杂的行为表型只有小到中等的影响(O'Donovan 等人,2008)。